A new review reports that nine people taking semaglutide and tirzepatide — the active ingredient in GLP-1 medications — experienced vision issues, including three potentially blinding eye conditions.
Engineering students like An Le (left) and Bo Wen (center) work with Professor Truong Nguyen (right) to develop AI tools that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback